AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
InnoCare Pharma Limited
Video analysis: INCPF
All videosNo video analysis for this stock yet. Request one from our team.
News: INCPF
InnoCare Pharma Limited (INCPF) Q2 2026 Earnings Call Transcript
InnoCare Pharma Limited (INCPF) Q2 2026 Earnings Call Transcript
China's Innocare's psoriasis drug meets main goal in late-stage trial
China-based Innocare Pharma said on Monday the Phase III trial of fadeucravacitinib, an experimental treatment for moderate-to-severe plaque psoriasis, has met its primary endpoint.
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
BEIJING, July 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the clinical trial of novel CDH17 targeted ADC, ICP-B208, in China. Developed from InnoCare's in-house ADC platform, ICP-B208 is a novel ADC comprising a humanized anti-CDH17 monoclonal antibody conjugated to a potent, in-house invented payload via a protease-cleavable linker.
Similar companies
-
Shanghai Junshi Biosciences Co., Ltd.
SHJBF
·
Other OTC
Compare
-
Genscript Biotech Corporation
GNNSF
·
Other OTC
Compare
-
ALK-Abelló A/S
AKBLF
·
Other OTC
Compare
-
Laboratorios Farmaceuticos Rovi, S.A.
LABFF
·
Other OTC
Compare
-
Zealand Pharma A/S
ZLDPF
·
Other OTC
Compare
-
Camurus AB
CAMRF
·
Other OTC
Compare